



ASX ANNOUNCEMENT

2 April 2024

Cardiex Completes HEARTsense Wearable Study and Secures US Wearable Patent

Cardiex Limited (ASX: CDX) (the **Company**) is pleased to announce the successful completion of two significant milestones in the commercialization of its wearable biomarker technology.

Successful Completion of HEARTsense Wearable Study.

The Company has successfully completed its primary study validating the use of its SphygmoCor® biomarker technology in wearables by way of a PPG (Photoplethysmogram) sensor (the “HEARTsense Study”). The objective of the HEARTsense Study was to successfully demonstrate the ability to extract vascular biomarkers from a wearable PPG sensor that could previously only be achieved with the Company’s “gold standard” XCEL biometric monitor, and the soon to be released Pulse biometric monitor.

The XCEL biometric monitor is the market leader in measuring central non-invasive vascular biomarkers and is used by all top 20 US hospitals, global pharmaceutical companies (47 clinical trials), research (2300+ research papers), and in specialist clinical practices. The HEARTsense Study showed that that same proprietary XCEL technology can now be ported into a wearable device in a format compatible with commonly used wearable sensor devices.

Completion of the HEARTsense study is also a key step for the Company as it prepares to lodge its FDA submission for clearance of its CONNEQT Band wearable technology in Q1 FY2025, as well as being a key step towards commercialization.

Commenting on the results of the HEARTsense Study, Cardiex CEO Craig Cooper stated:

“This is a significant achievement for the Company as well as being a game changer for the medical technology industry. This is the first time that medical-grade measurements of arterial health, arterial stiffness, and vascular age have been made by way of a finger-based PPG sensor in a wearable; opening the path to commercialization in a number of device formats.

Our technology strategy has always been to produce products that can be deployed in medical and consumer settings for clinics, in the home, and when on-the-go. Importantly, it's our focus on medical-grade wearable solutions which distinguishes us from other companies. The HEARTsense Study is a strong validation of that strategy as well as being a key step towards FDA clearance of our CONNEQT Band wearable technology.”

Results of the HEARTsense Study are in the process of being submitted for publication in leading peer-reviewed medical and scientific journals.

Cardiex Secures Patent for CONNEQT Band Wearable Technology.

In a significant advancement for the health and wellness industry, Cardiex has also been awarded another patent (US 2021/0369129 A1) for its CONNEQT Band wearable technology ("US Patents and Trademarks Office - WEARABLE DEVICE WITH PHOTOPLETHYSMOGRAM SENSOR"). This development marks another significant milestone for the Company, introducing an innovative approach to personal health monitoring. The CONNEQT Band technology patent employs a unique PPG sensor enabling the precise capture of key biometric indicators of disease not available on any current wearable health device.

The CONNEQT Band technology patent overcomes the limitations of traditional health monitoring methods with a novel sensor placed on the side of wearables to capture arterial signals from the fingertips.

Importantly, with the securing of this new patent, Cardiex now holds exclusive rights to market, sell, or license its wearable health technology in a number of device formats.

Highlighting the transformative impact of the CONNEQT Band technology Cooper stated:

"We are thrilled to announce that Cardiex has secured the first patent of its kind for a wearable technology system, enabling us to both launch our own devices and to forge partnerships and license our technology to other leading brands looking to deploy FDA-cleared, medical grade health solutions. This breakthrough allows for a deeper exploration of the body's health metrics and unlocks the ability to now achieve medical-grade arterial health monitoring directly from the wrist.

We strongly believe that we are uniquely positioned to create a significant opportunity for shareholders in the wearable healthtech space. Our focus will continue to be on developing and deploying medical grade biomarkers which can be used by both consumers, and importantly, clinicians, to better understand and prevent vascular disease. Currently, there is not a single wearable that is medically validated for use for monitoring vascular disease in the USA. This is the opportunity that we are pursuing and which is supported by our 20+ years of experience, patent portfolio, and validation studies on our wearable technology."

The patent for the CONNEQT Band is a reflection of Cardiex's commitment to pioneering new health monitoring solutions, adding to an existing portfolio of patents that demonstrate the Company's expertise and leadership in wearable technology. This achievement is part of a broader strategy to enhance and expand the applications of its technologies in both medical and wellness settings.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").